EcoR1 Capital LLC Has $77.91 Million Stock Position in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

EcoR1 Capital LLC increased its stake in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 466.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,115,000 shares of the company’s stock after purchasing an additional 2,565,000 shares during the period. Centessa Pharmaceuticals accounts for 3.5% of EcoR1 Capital LLC’s portfolio, making the stock its 5th largest holding. EcoR1 Capital LLC owned about 2.32% of Centessa Pharmaceuticals worth $77,906,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. raised its position in Centessa Pharmaceuticals by 26.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,688 shares of the company’s stock worth $117,000 after purchasing an additional 979 shares during the last quarter. TD Waterhouse Canada Inc. bought a new position in Centessa Pharmaceuticals in the 4th quarter worth approximately $25,000. Wells Fargo & Company MN raised its position in Centessa Pharmaceuticals by 42.4% in the 4th quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock worth $85,000 after purchasing an additional 1,008 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Centessa Pharmaceuticals in the 4th quarter worth approximately $36,000. Finally, T. Rowe Price Investment Management Inc. raised its position in Centessa Pharmaceuticals by 7,580.0% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock worth $39,000 after purchasing an additional 1,516 shares during the last quarter. Institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Price Performance

CNTA opened at $39.87 on Thursday. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.23. Centessa Pharmaceuticals PLC Sponsored ADR has a 12 month low of $12.30 and a 12 month high of $40.26. The company has a fifty day simple moving average of $39.65 and a 200 day simple moving average of $31.11. The stock has a market cap of $6.17 billion, a P/E ratio of -22.27 and a beta of 1.11.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.14). On average, research analysts expect that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 EPS for the current year.

Insider Activity at Centessa Pharmaceuticals

In related news, insider Karen M. Anderson sold 41,076 shares of the company’s stock in a transaction on Thursday, March 26th. The shares were sold at an average price of $30.12, for a total value of $1,237,209.12. Following the completion of the sale, the insider owned 62,085 shares in the company, valued at $1,870,000.20. This represents a 39.82% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 4.09% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

CNTA has been the subject of several research analyst reports. Wells Fargo & Company cut shares of Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and boosted their price objective for the stock from $35.00 to $42.00 in a research report on Monday, April 20th. Guggenheim cut shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 2nd. Wolfe Research cut shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a research report on Tuesday, March 31st. Truist Financial cut shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 target price for the company. in a research report on Monday, April 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research report on Monday, April 20th. Four analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Centessa Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $41.33.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.